clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Arthritis D001168 41 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Abscess D000038 13 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Gastritis D005756 27 associated lipids
Heart Failure D006333 36 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Rodent Diseases D012376 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Pancreatitis D010195 10 associated lipids
Skin Ulcer D012883 6 associated lipids
Cysts D003560 4 associated lipids
Urination Disorders D014555 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Pilotto A et al. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. 2000 Aliment. Pharmacol. Ther. pmid:10930903
Kihira K et al. Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. 2000 Aliment. Pharmacol. Ther. pmid:10930904
Gatta L et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. 2005 Aliment. Pharmacol. Ther. pmid:15963079
Peterson WL The role of antisecretory drugs in the treatment of Helicobacter pylori infection. 1997 Aliment. Pharmacol. Ther. pmid:9146787
Sierra F et al. Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. 2013 Aliment. Pharmacol. Ther. pmid:23656465
Kondo Y et al. Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. 2004 Aliment. Pharmacol. Ther. pmid:15298609
Di Mario F et al. Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. 2006 Aliment. Pharmacol. Ther. pmid:16611285
Borody TJ et al. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. 2006 Aliment. Pharmacol. Ther. pmid:16441468
Nagahara A et al. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. 2001 Aliment. Pharmacol. Ther. pmid:11207518
Bardhan KD et al. Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. 2000 Aliment. Pharmacol. Ther. pmid:10632646
Axon AT et al. Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. 1997 Aliment. Pharmacol. Ther. pmid:9042977
Calvet X et al. One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. 2002 Aliment. Pharmacol. Ther. pmid:12144575
Spinzi GC et al. Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. 1998 Aliment. Pharmacol. Ther. pmid:9663722
O'Connor HJ et al. Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? 1998 Aliment. Pharmacol. Ther. pmid:9570262
Goodgame RW et al. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. 2001 Aliment. Pharmacol. Ther. pmid:11736715
Gené E et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. 2003 Aliment. Pharmacol. Ther. pmid:12752350
Cammarota G et al. Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. 1996 Aliment. Pharmacol. Ther. pmid:8971300
Pilotto A et al. Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. 1996 Aliment. Pharmacol. Ther. pmid:8971305
Nista EC et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. 2003 Aliment. Pharmacol. Ther. pmid:12969089
Klok RM et al. Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. 2002 Aliment. Pharmacol. Ther. pmid:11966514